tradingkey.logo
tradingkey.logo

Mediwound Ltd

MDWD
View Detailed Chart
15.580USD
-0.130-0.83%
Market hours ETQuotes delayed by 15 min
34.91MMarket Cap
LossP/E TTM

Mediwound Ltd

15.580
-0.130-0.83%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.83%

5 Days

-8.14%

1 Month

-9.94%

6 Months

-13.30%

Year to Date

-15.60%

1 Year

-2.32%

View Detailed Chart

TradingKey Stock Score of Mediwound Ltd

Currency: USD Updated: 2026-03-27

Key Insights

Mediwound Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 93 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.80.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mediwound Ltd's Score

Industry at a Glance

Industry Ranking
93 / 157
Overall Ranking
238 / 4542
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Mediwound Ltd Highlights

StrengthsRisks
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.96M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 16.96M.
Fairly Valued
The company’s latest PE is -7.17, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.94M shares, increasing 18.34% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 3.69K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.19.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
29.800
Target Price
+89.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mediwound Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Mediwound Ltd Info

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Ticker SymbolMDWD
CompanyMediwound Ltd
CEOGonen (Ofer)
Websitehttps://www.mediwound.com/
KeyAI